Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | PARP1 | P09874 | 3/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | PTPN5 | P54829 | 1/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | MAOA | P21397 | 1/20 | 0.47 |
| ▸ | MMP8 | P22894 | 1/20 | 0.46 |
| ▸ | MMP13 | P45452 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14073632 | 0.87 | MAPT (0.56) | KMT2AMEN1ALDH1A1HSD17B10LMNA | |
| SCHEMBL14073116 | 0.81 | PARP1 (0.62) | KMT2APARP1ALDH1A1TSHRLMNA | |
| SCHEMBL14073911 | 0.81 | MAPT (0.56) | ALDH1A1HSD17B10TSHRLMNAKDM4E | |
| SCHEMBL14073235 | 0.80 | HTT (0.69) | KMT2AMEN1PARP1ALDH1A1TSHR | |
| SCHEMBL14073051 | 0.80 | PARP1 (0.70) | KMT2APARP1ALDH1A1TSHRLMNA | |
| SCHEMBL14073081 | 0.79 | TSHR (0.50) | KMT2APARP1ALDH1A1TSHRLMNA | |
| SCHEMBL14073044 | 0.78 | TSHR (0.73) | KMT2APARP1ALDH1A1HSD17B10TSHR | |
| SCHEMBL14073079 | 0.77 | TSHR (0.48) | KMT2APARP1ALDH1A1TSHRLMNA | |
| SCHEMBL8194816 | 0.77 | PARP1 (0.54) | KMT2APARP1TSHRLMNAKDM4E | |
| SCHEMBL14073349 | 0.77 | PARP1 (0.56) | KMT2APARP1ALDH1A1TSHRLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080221093-A1 | Metalloprotease inhibitors containing a heterocyclic moiety | ALANTOS PHARMACEUTICALS HOLDING, INC. | 2008-09-11 | — | — | US | disclosed |
| US-20080221093-A1 | Metalloprotease inhibitors containing a heterocyclic moiety | ALANTOS PHARMACEUTICALS HOLDING, INC. | 2008-09-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080221093-A1 | Metalloprotease inhibitors containing a heterocyclic moiety | MMP12, MMP13, MMP25 | KMT2A 2900/4885MEN1 1893/4885PARP1 327/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.